Upadacitinib in refractory cutaneous pseudolymphoma: A case report

Cutaneous pseudolymphoma is a benign condition characterized by a reactive B-cell, T-cell or mixed lymphoproliferative process. Different causative agents (e.g. injected substances, tattoo, drugs and insect bites) have been described, but in many cases no cause can be identified; hence, the term idiopathic cutaneous pseudolymphoma. There are no specific guidelines for the treatment of cutaneous pseudolymphoma, and sometimes a few cases are refractory to conventional treatments. We describe a case of a 41-year-old African woman with refractory facial IgG4 pseudolymphoma successfully treated with upadacitinib.

Authors

Institutions

Publication Details

Journal
SAGE Open Medical Case Reports
Published
2025-06-19
DOI
https://doi.org/10.1177/2050313x251350370
Primary Topic
Cutaneous lymphoproliferative disorders research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Upadacitinib in refractory cutaneous pseudolymphoma: A case report

Chiara Colato, Paolo Gisondi, Elisabetta Danese, Francesco Bellinato et al.
1 links
SAGE Open Medical Case Reports
Cutaneous lymphoproliferative disorders research
article

Upadacitinib in refractory cutaneous pseudolymphoma: A case report

Chiara Colato, Paolo Gisondi, Elisabetta Danese, Francesco Bellinato, Giampiero Girolomoni, Tea Curic
article en

Abstract

Cutaneous pseudolymphoma is a benign condition characterized by a reactive B-cell, T-cell or mixed lymphoproliferative process. Different causative agents (e.g. injected substances, tattoo, drugs and insect bites) have been described, but in many cases no cause can be identified; hence, the term idiopathic cutaneous pseudolymphoma. There are no specific guidelines for the treatment of cutaneous pseudolymphoma, and sometimes a few cases are refractory to conventional treatments. We describe a case of a 41-year-old African woman with refractory facial IgG4 pseudolymphoma successfully treated with upadacitinib.

SAGE Open Medical Case ReportsVol. 13
University of Verona (IT)
Good health and well-being
Openalex Percentile: Top 75%
Cutaneous lymphoproliferative disorders research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.